{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T19:14:26Z","timestamp":1789845266537,"version":"4.0.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01738-4","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T02:49:29Z","timestamp":1750819769000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk of new or recurrent cancer during treatment with biologics in patients with immune-mediated inflammatory diseases and previous cancer: a meta-analysis"],"prefix":"10.1007","volume":"25","author":[{"given":"Daniel","family":"Isufi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Willy","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel Bak","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Seidelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"3","key":"1738_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1053\/J.GASTRO.2019.08.027","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology. 2020;158(3):562-572.e12. https:\/\/doi.org\/10.1053\/J.GASTRO.2019.08.027.","journal-title":"Gastroenterology"},{"issue":"8","key":"1738_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMCT1209614","volume":"369","author":"OH Nielsen","year":"2013","unstructured":"Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. 2013;369(8):754\u201362. https:\/\/doi.org\/10.1056\/NEJMCT1209614.","journal-title":"N Engl J Med"},{"key":"1738_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/RAP\/RKAA070","author":"K Geale","year":"2020","unstructured":"Geale K, Lindberg I, Paulsson EC, et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020. https:\/\/doi.org\/10.1093\/RAP\/RKAA070.","journal-title":"Rheumatol Adv Pract"},{"issue":"3","key":"1738_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/S10620-021-06932-4","volume":"67","author":"S Honap","year":"2022","unstructured":"Honap S, Meade S, Ibraheim H, Irving PM, Jones MP, Samaan MA. Effectiveness and safety of ustekinumab in inflammatory bowel disease: a systematic review and meta-analysis. Dig Dis Sci. 2022;67(3):1018\u201335. https:\/\/doi.org\/10.1007\/S10620-021-06932-4.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"1738_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/S40257-021-00603-W","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol. 2021;22(4):425\u201342. https:\/\/doi.org\/10.1007\/S40257-021-00603-W.","journal-title":"Am J Clin Dermatol"},{"key":"1738_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2017.00460","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol. 2017. https:\/\/doi.org\/10.3389\/FPHAR.2017.00460.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1738_CR7","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/APT.12644","volume":"39","author":"RW Stidham","year":"2014","unstructured":"Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014;39(7):660\u201371. https:\/\/doi.org\/10.1111\/APT.12644.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1738_CR8","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/APT.12749","volume":"39","author":"RW Stidham","year":"2014","unstructured":"Stidham RW, Lee TCH, Higgins PDR, et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn\u2019s disease. Aliment Pharmacol Ther. 2014;39(12):1349\u201362. https:\/\/doi.org\/10.1111\/APT.12749.","journal-title":"Aliment Pharmacol Ther"},{"key":"1738_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.PUB6","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD011535.PUB6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1738_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0030275","volume":"7","author":"KJ Aaltonen","year":"2012","unstructured":"Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordstr\u00f6m DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE. 2012;7(1): e30275. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0030275.","journal-title":"PLoS ONE"},{"issue":"6","key":"1738_CR11","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/ART.20311","volume":"50","author":"F Wolfe","year":"2004","unstructured":"Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti\u2013tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004;50(6):1740\u201351. https:\/\/doi.org\/10.1002\/ART.20311.","journal-title":"Arthritis Rheum"},{"issue":"19","key":"1738_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/JAMA.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275\u201385. https:\/\/doi.org\/10.1001\/JAMA.295.19.2275.","journal-title":"JAMA"},{"issue":"11","key":"1738_CR13","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/GUTJNL-2013-305300","volume":"62","author":"O Bernheim","year":"2013","unstructured":"Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013;62(11):1523\u20138. https:\/\/doi.org\/10.1136\/GUTJNL-2013-305300.","journal-title":"Gut"},{"issue":"1","key":"1738_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/J.CGH.2015.07.037","volume":"14","author":"J Axelrad","year":"2016","unstructured":"Axelrad J, Bernheim O, Colombel JF, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(1):58\u201364. https:\/\/doi.org\/10.1016\/J.CGH.2015.07.037.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"1738_CR15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1136\/GUTJNL-2013-305763","volume":"63","author":"L Beaugerie","year":"2014","unstructured":"Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63(9):1416\u201323. https:\/\/doi.org\/10.1136\/GUTJNL-2013-305763.","journal-title":"Gut"},{"issue":"6","key":"1738_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/ACR.20129","volume":"62","author":"WG Dixon","year":"2010","unstructured":"Dixon WG, Watson KD, Lunt M, et al. Influence of anti\u2013tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for rheumatology biologics register. Arthritis Care Res (Hoboken). 2010;62(6):755\u201363. https:\/\/doi.org\/10.1002\/ACR.20129.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"1738_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/GUT.2005.075937","volume":"55","author":"L Biancone","year":"2006","unstructured":"Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn\u2019s disease: a multicentre matched pair study. Gut. 2006;55(2):228\u201333. https:\/\/doi.org\/10.1136\/GUT.2005.075937.","journal-title":"Gut"},{"issue":"4","key":"1738_CR18","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135\/SUPPL_FILE\/PRISMA_FIGURE-S1.DOC","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139. https:\/\/doi.org\/10.7326\/0003-4819-151-4-200908180-00135\/SUPPL_FILE\/PRISMA_FIGURE-S1.DOC.","journal-title":"Ann Intern Med"},{"key":"1738_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/S13643-016-0384-4","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev. 2016. https:\/\/doi.org\/10.1186\/S13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"1738_CR20","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org\/. Accessed 3 Sept 2024."},{"key":"1738_CR21","doi-asserted-by":"publisher","DOI":"10.1201\/9781003107347","volume-title":"Doing meta-analysis with R: a hands-on guide","author":"M Harrer","year":"2021","unstructured":"Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R: a hands-on guide. 1st ed. Chapman & Hall\/CRC Press; 2021.","edition":"1"},{"issue":"3","key":"1738_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"1738_CR23","unstructured":"Deeks J, Higgins J, Altman D, et al., editors. Chapter 10: Analysing data and undertaking meta-analyses | Cochrane Training. In: Cochrane; 2023. www.training.cochrane.org\/handbook. Accessed 3 Sept 2024."},{"issue":"6","key":"1738_CR24","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1111\/JGH.15806","volume":"37","author":"B Hasan","year":"2022","unstructured":"Hasan B, Tandon KS, Miret R, et al. Ustekinumab does not increase risk of new or recurrent cancer in inflammatory bowel disease patients with prior malignancy. J Gastroenterol Hepatol. 2022;37(6):1016\u201321. https:\/\/doi.org\/10.1111\/JGH.15806.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"1738_CR25","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/IBD\/IZAC035","volume":"28","author":"SJ Hong","year":"2022","unstructured":"Hong SJ, Zenger C, Pecoriello J, et al. Ustekinumab and vedolizumab are not associated with subsequent cancer in IBD patients with prior malignancy. Inflamm Bowel Dis. 2022;28(12):1826. https:\/\/doi.org\/10.1093\/IBD\/IZAC035.","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"1738_CR26","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1093\/RHEUMATOLOGY\/KEW314","volume":"55","author":"L Silva-Fern\u00e1ndez","year":"2016","unstructured":"Silva-Fern\u00e1ndez L, Lunt M, Kearsley-Fleet L, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. Rheumatology (Oxford). 2016;55(11):2033. https:\/\/doi.org\/10.1093\/RHEUMATOLOGY\/KEW314.","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"1738_CR27","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1136\/ANNRHEUMDIS-2014-205745","volume":"74","author":"P Raaschou","year":"2015","unstructured":"Raaschou P, Frisell T, Askling J. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015;74(12):2137\u201343. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2014-205745.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1738_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/ANNRHEUMDIS-2011-200622","volume":"71","author":"LK Mercer","year":"2012","unstructured":"Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2012;71(6):869\u201374. https:\/\/doi.org\/10.1136\/ANNRHEUMDIS-2011-200622.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1738_CR29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/JAMADERMATOL.2020.0024","volume":"156","author":"S Vaengebjerg","year":"2020","unstructured":"Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(4):421\u20139. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2020.0024.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"1738_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/1744666X.2020.1754194","volume":"16","author":"ND Loft","year":"2020","unstructured":"Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: Should we be paying more attention? Expert Rev Clin Immunol. 2020;16(5):479\u201392. https:\/\/doi.org\/10.1080\/1744666X.2020.1754194.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"1738_CR31","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/JAMADERMATOL.2015.3029","volume":"152","author":"FI Scott","year":"2016","unstructured":"Scott FI, Mamtani R, Brensinger CM, et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol. 2016;152(2):164\u201372. https:\/\/doi.org\/10.1001\/JAMADERMATOL.2015.3029.","journal-title":"JAMA Dermatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01738-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01738-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:46:03Z","timestamp":1764917163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01738-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1738"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01738-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]},"assertion":[{"value":"28 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mr. Isufi, Dr. Schwarz, and Dr. Jensen report no conflict of interest. Dr. Loft has been a paid speaker for Eli Lilly, Janssen Cilag, and Sandoz. Dr. Seidelin has received research grants from Takeda, Janssen, the Danish Research Council, and the Capital Region Denmark; and has served as the national coordinator of studies for AbbVie, Arena Pharmaceuticals, Ely Lilly, and Boehringer Ingelheim. Dr. Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis, Pfizer, and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, Boehringer Ingelheim, LEO Pharma, Takeda, Stada, UCB, Almirall, Bristol-Myers Squibb, and Sanofi and has received research and educational grants\/funding from LEO Foundation, Kgl Hofbundtmager Aage Bang Foundation, Sanofi, Bristol-Myers Squibb, Janssen Cilag, and Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"219"}}